Display options
Cite
Tan S, Xia L, Yi P, et al. Exosomal miRNAs in tumor microenvironment. J Exp Clin Cancer Res. 2020;39(1):67doi: 10.1186/s13046-020-01570-6.
Tan, S., Xia, L., Yi, P., Han, Y., Tang, L., Pan, Q., Tian, Y., Rao, S., Oyang, L., Liang, J., Lin, J., Su, M., Shi, Y., Cao, D., Zhou, Y., & Liao, Q. (2020). Exosomal miRNAs in tumor microenvironment. Journal of experimental & clinical cancer research : CR, 39(1), 67. https://doi.org/10.1186/s13046-020-01570-6
Tan, Shiming, et al. "Exosomal miRNAs in tumor microenvironment." Journal of experimental & clinical cancer research : CR vol. 39,1 (2020): 67. doi: https://doi.org/10.1186/s13046-020-01570-6
Tan S, Xia L, Yi P, Han Y, Tang L, Pan Q, Tian Y, Rao S, Oyang L, Liang J, Lin J, Su M, Shi Y, Cao D, Zhou Y, Liao Q. Exosomal miRNAs in tumor microenvironment. J Exp Clin Cancer Res. 2020 Apr 16;39(1):67. doi: 10.1186/s13046-020-01570-6. PMID: 32299469; PMCID: PMC7164281.
Copy Download .nbib Format: NLM
Share it on

J Exp Clin Cancer Res. 2020 Apr 16;39(1):67. doi: 10.1186/s13046-020-01570-6.

Exosomal miRNAs in tumor microenvironment.

Journal of experimental & clinical cancer research : CR

Shiming Tan, Longzheng Xia, Pin Yi, Yaqian Han, Lu Tang, Qing Pan, Yutong Tian, Shan Rao, Linda Oyang, Jiaxin Liang, Jinguan Lin, Min Su, Yingrui Shi, Deliang Cao, Yujuan Zhou, Qianjin Liao

Affiliations

  1. Hunan Key Laboratory of Translational Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 283 Tongzipo Road, Changsha, 410013, Hunan, China.
  2. University of South China, Hengyang, 421001, Hunan, China.
  3. Department of Medical Microbiology, Immunology & Cell Biology, Simmons Cancer Institute, Southern Illinois University School of Medicine, 913 N. Rutledge Street, Springfield, IL 62794,, USA.
  4. Hunan Key Laboratory of Translational Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 283 Tongzipo Road, Changsha, 410013, Hunan, China. [email protected].
  5. Hunan Key Laboratory of Translational Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 283 Tongzipo Road, Changsha, 410013, Hunan, China. [email protected].

PMID: 32299469 PMCID: PMC7164281 DOI: 10.1186/s13046-020-01570-6

Abstract

Tumor microenvironment (TME) is the internal environment in which tumor cells survive, consisting of tumor cells, fibroblasts, endothelial cells, and immune cells, as well as non-cellular components, such as exosomes and cytokines. Exosomes are tiny extracellular vesicles (40-160nm) containing active substances, such as proteins, lipids and nucleic acids. Exosomes carry biologically active miRNAs to shuttle between tumor cells and TME, thereby affecting tumor development. Tumor-derived exosomal miRNAs induce matrix reprogramming in TME, creating a microenvironment that is conducive to tumor growth, metastasis, immune escape and chemotherapy resistance. In this review, we updated the role of exosomal miRNAs in the process of TME reshaping.

Keywords: CAFs; angiogenesis; exosomal miRNAs; immune microenvironment; tumor microenvironment (TME)

References

  1. Pharmacol Ther. 2018 Aug;188:1-11 - PubMed
  2. Blood. 2012 Jan 19;119(3):756-66 - PubMed
  3. J Hematol Oncol. 2020 Jan 31;13(1):10 - PubMed
  4. Br J Cancer. 2019 Jan;120(1):45-53 - PubMed
  5. Cell Rep. 2016 Oct 11;17(3):799-808 - PubMed
  6. Transl Oncol. 2019 Aug;12(8):1038-1044 - PubMed
  7. Biomed Pharmacother. 2019 Jan;109:1032-1040 - PubMed
  8. Mol Carcinog. 2019 Mar;58(3):376-387 - PubMed
  9. Dev Biol. 2019 May 15;449(2):115-121 - PubMed
  10. Mol Cancer. 2020 Feb 27;19(1):43 - PubMed
  11. Cancer Metastasis Rev. 2018 Dec;37(4):577-597 - PubMed
  12. Int J Mol Sci. 2018 May 21;19(5): - PubMed
  13. Cell Rep. 2020 Feb 18;30(7):2065-2074.e4 - PubMed
  14. Nat Commun. 2018 Feb 22;9(1):771 - PubMed
  15. Oncogene. 2018 Aug;37(31):4239-4259 - PubMed
  16. Cytokine Growth Factor Rev. 2020 Feb;51:75-83 - PubMed
  17. Cancers (Basel). 2020 Jan 02;12(1): - PubMed
  18. J Invest Dermatol. 2018 Jan;138(1):89-97 - PubMed
  19. Mol Ther Nucleic Acids. 2019 Jun 7;16:791-804 - PubMed
  20. Oncogene. 2017 Oct 19;36(42):5861-5873 - PubMed
  21. Prostate. 2017 May;77(6):573-583 - PubMed
  22. Cells. 2020 Jan 15;9(1): - PubMed
  23. J Exp Clin Cancer Res. 2019 Feb 22;38(1):99 - PubMed
  24. J Extracell Vesicles. 2020 Jan 22;9(1):1716513 - PubMed
  25. Cell Oncol (Dordr). 2017 Oct;40(5):457-470 - PubMed
  26. Allergy Asthma Clin Immunol. 2019 May 20;15:33 - PubMed
  27. Oncoimmunology. 2017 Nov 27;7(3):e1395126 - PubMed
  28. Sci Rep. 2016 Dec 08;6:38750 - PubMed
  29. Oncotarget. 2017 May 30;8(22):36137-36148 - PubMed
  30. BMC Genomics. 2012 Aug 01;13:357 - PubMed
  31. Int J Mol Sci. 2019 Jun 29;20(13): - PubMed
  32. J Control Release. 2019 Sep 10;309:173-180 - PubMed
  33. Nat Rev Cancer. 2017 Aug;17(8):457-474 - PubMed
  34. J Extracell Vesicles. 2019 Nov 29;9(1):1697028 - PubMed
  35. Oncogene. 2017 Aug 24;36(34):4929-4942 - PubMed
  36. Endocr Relat Cancer. 2019 May;26(5):525-538 - PubMed
  37. Cells. 2019 Sep 08;8(9): - PubMed
  38. Oncol Lett. 2019 Mar;17(3):3055-3065 - PubMed
  39. J Exp Clin Cancer Res. 2018 Jul 13;37(1):147 - PubMed
  40. Biochimie. 2019 Jan;156:148-157 - PubMed
  41. Oncogene. 2020 Mar;39(12):2539-2549 - PubMed
  42. Nat Rev Clin Oncol. 2018 Oct;15(10):617-638 - PubMed
  43. Sci Rep. 2019 Oct 25;9(1):15329 - PubMed
  44. Cell Immunol. 2014 Nov-Dec;292(1-2):65-9 - PubMed
  45. J Cell Biochem. 2019 Aug;120(8):13187-13201 - PubMed
  46. Adv Exp Med Biol. 2018;1056:87-108 - PubMed
  47. Mol Ther Nucleic Acids. 2018 Jun 1;11:243-252 - PubMed
  48. Cancer Lett. 2020 Apr 28;476:13-22 - PubMed
  49. Mol Cancer. 2020 Feb 15;19(1):29 - PubMed
  50. Oncotarget. 2016 Jul 12;7(28):43076-43087 - PubMed
  51. Oncogene. 2019 Feb;38(8):1256-1268 - PubMed
  52. Cancer Cell. 2012 Mar 20;21(3):309-22 - PubMed
  53. Cancer Res. 2010 Dec 1;70(23):9621-30 - PubMed
  54. Theranostics. 2019 Jul 9;9(16):4779-4794 - PubMed
  55. Cell. 2019 Apr 4;177(2):428-445.e18 - PubMed
  56. Cancer Lett. 2020 Feb 1;470:126-133 - PubMed
  57. J Extracell Vesicles. 2014 Mar 26;3: - PubMed
  58. Nat Biomed Eng. 2020 Jan;4(1):9-11 - PubMed
  59. Biomed Pharmacother. 2018 Dec;108:646-655 - PubMed
  60. Nat Commun. 2018 Jan 15;9(1):191 - PubMed
  61. Nat Commun. 2013;4:2980 - PubMed
  62. ACS Nano. 2018 Sep 25;12(9):8977-8993 - PubMed
  63. Life Sci. 2019 Feb 15;219:152-162 - PubMed
  64. Nat Commun. 2018 Dec 19;9(1):5395 - PubMed
  65. Curr Opin Cell Biol. 2014 Aug;29:116-25 - PubMed
  66. Cancer Res. 2018 Apr 1;78(7):1833-1844 - PubMed
  67. J Ovarian Res. 2019 Jan 22;12(1):6 - PubMed
  68. ACS Appl Mater Interfaces. 2018 Nov 21;10(46):39478-39486 - PubMed
  69. Cancer Cell. 2019 Oct 14;36(4):418-430.e6 - PubMed
  70. Nat Commun. 2016 Nov 24;7:13588 - PubMed
  71. Cell Death Differ. 2016 Jan;23(1):132-45 - PubMed
  72. Front Oncol. 2018 Mar 20;8:66 - PubMed
  73. J Pathol. 2019 Feb;247(2):241-253 - PubMed
  74. Oncoimmunology. 2018 Aug 1;7(9):e1470729 - PubMed
  75. Cancer Cell. 2014 Apr 14;25(4):501-15 - PubMed
  76. Cell Death Dis. 2016 Jul 28;7(7):e2312 - PubMed
  77. Nat Cell Biol. 2018 May;20(5):597-609 - PubMed
  78. Int J Cancer. 2019 Jan 15;144(2):322-333 - PubMed
  79. Adv Sci (Weinh). 2019 Oct 23;6(24):1901779 - PubMed
  80. Eur J Pharmacol. 2019 Aug 15;857:172449 - PubMed
  81. Front Oncol. 2019 May 03;9:356 - PubMed
  82. Cancer Res. 2018 Sep 1;78(17):4957-4970 - PubMed
  83. Cancers (Basel). 2020 Feb 17;12(2): - PubMed
  84. Science. 2020 Feb 7;367(6478): - PubMed
  85. Front Immunol. 2020 Feb 11;11:13 - PubMed
  86. Front Immunol. 2019 Dec 10;10:2876 - PubMed
  87. Cancer Res. 2016 Apr 1;76(7):1677-82 - PubMed
  88. Noncoding RNA. 2019 Mar 21;5(1): - PubMed
  89. Front Immunol. 2019 Aug 21;10:1987 - PubMed
  90. Cytotherapy. 2018 Mar;20(3):291-301 - PubMed
  91. Onco Targets Ther. 2018 Jan 09;11:291-299 - PubMed
  92. Adv Drug Deliv Rev. 2019 Mar 15;143:37-67 - PubMed
  93. Philos Trans R Soc Lond B Biol Sci. 2018 Jan 5;373(1737): - PubMed
  94. Neoplasia. 2018 Aug;20(8):775-788 - PubMed
  95. Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228 - PubMed
  96. Cancer Biol Ther. 2018 Jan 2;19(1):3-12 - PubMed
  97. Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):2204-2209 - PubMed
  98. Semin Immunol. 2018 Feb;35:69-79 - PubMed
  99. Leukemia. 2017 Apr;31(4):985-988 - PubMed
  100. Oncogene. 2019 Dec;38(49):7399-7415 - PubMed
  101. Pharmacol Res. 2020 Mar;153:104683 - PubMed
  102. Cancers (Basel). 2019 Jul 04;11(7): - PubMed
  103. Mol Cell Biochem. 2019 Apr;454(1-2):177-189 - PubMed
  104. Cell. 2019 Nov 14;179(5):1033-1055 - PubMed
  105. J Clin Invest. 2016 Apr 1;126(4):1208-15 - PubMed
  106. Oxid Med Cell Longev. 2018 Dec 2;2018:7042105 - PubMed
  107. Clin Cancer Res. 2018 Jun 15;24(12):2944-2950 - PubMed
  108. IUBMB Life. 2019 May;71(5):587-600 - PubMed
  109. J Exp Clin Cancer Res. 2018 Oct 3;37(1):242 - PubMed
  110. Nat Rev Immunol. 2020 Apr;20(4):209-215 - PubMed
  111. Int J Cancer. 2019 Mar 15;144(6):1444-1452 - PubMed
  112. Bull Cancer. 2018 Apr;105(4):336-349 - PubMed
  113. Cell Rep. 2014 Sep 25;8(6):1649-1658 - PubMed
  114. DNA Cell Biol. 2017 Mar;36(3):202-211 - PubMed
  115. Cell Rep. 2020 Feb 25;30(8):2489-2500.e5 - PubMed
  116. Mol Cancer. 2019 Mar 1;18(1):32 - PubMed
  117. J Clin Invest. 2019 Dec 2;129(12):5537-5552 - PubMed
  118. J Natl Cancer Inst. 2017 Oct 1;109(10): - PubMed
  119. Oral Dis. 2019 Aug 7;: - PubMed
  120. J Biol Chem. 2013 Apr 12;288(15):10849-59 - PubMed
  121. J Hematol Oncol. 2019 Aug 22;12(1):84 - PubMed
  122. Cell Physiol Biochem. 2017;44(5):1741-1748 - PubMed
  123. Nat Commun. 2015 Jul 02;6:7353 - PubMed
  124. Mol Cancer. 2019 Apr 2;18(1):76 - PubMed
  125. Oncogenesis. 2018 Jan 24;7(1):10 - PubMed
  126. Oncol Lett. 2018 Mar;15(3):3760-3765 - PubMed
  127. Cell Rep. 2016 May 3;15(5):978-987 - PubMed
  128. Nat Cell Biol. 2020 Feb;22(2):187-199 - PubMed
  129. J Cell Physiol. 2018 Sep;233(9):6359-6369 - PubMed
  130. J Extracell Vesicles. 2018 Nov 23;7(1):1535750 - PubMed
  131. Cancer Lett. 2020 Apr 10;475:2-13 - PubMed
  132. Nat Cell Biol. 2019 Jan;21(1):9-17 - PubMed
  133. Theranostics. 2019 Oct 18;9(26):8206-8220 - PubMed
  134. Cancer Lett. 2018 Oct 28;435:80-91 - PubMed
  135. Cancer Immunol Res. 2020 Feb;8(2):255-267 - PubMed
  136. Genome Biol. 2019 Jan 14;20(1):12 - PubMed
  137. Mol Cancer. 2018 Oct 11;17(1):147 - PubMed
  138. Mol Cancer. 2019 Mar 30;18(1):52 - PubMed
  139. Cell Physiol Biochem. 2018;49(3):869-883 - PubMed
  140. Cancer Res. 2018 Aug 15;78(16):4586-4598 - PubMed
  141. Cell Physiol Biochem. 2019;53(1):19-35 - PubMed
  142. Cancer Sci. 2019 Aug;110(8):2396-2407 - PubMed
  143. J Neuroinflammation. 2020 Feb 25;17(1):74 - PubMed
  144. J Nanobiotechnology. 2020 Jan 9;18(1):10 - PubMed
  145. Oncogene. 2018 May;37(21):2873-2889 - PubMed
  146. Molecules. 2018 Dec 10;23(12): - PubMed
  147. Mol Cancer Res. 2017 Sep;15(9):1287-1298 - PubMed
  148. Int J Cancer. 2019 Apr 1;144(7):1486-1495 - PubMed
  149. Sci Rep. 2018 Apr 17;8(1):6065 - PubMed
  150. Front Immunol. 2020 Jan 29;11:73 - PubMed
  151. Biomed Pharmacother. 2018 Oct;106:1135-1143 - PubMed
  152. Cancers (Basel). 2019 Dec 04;11(12): - PubMed
  153. Proc Natl Acad Sci U S A. 2018 Nov 27;115(48):12158-12163 - PubMed
  154. J Immunol. 2018 Aug 15;201(4):1306-1314 - PubMed
  155. Front Immunol. 2020 Jan 21;10:3137 - PubMed
  156. J Cell Physiol. 2019 Jun;234(6):9417-9427 - PubMed
  157. J Oncol. 2019 Jun 9;2019:6270784 - PubMed
  158. Cancer Lett. 2018 Jan 28;413:102-109 - PubMed
  159. Int J Cancer. 2019 Oct 15;145(8):2209-2224 - PubMed
  160. Cytotechnology. 2016 Dec;68(6):2223-2233 - PubMed
  161. Small GTPases. 2018 Nov 2;9(6):445-451 - PubMed
  162. J Hematol Oncol. 2019 Jan 25;12(1):10 - PubMed
  163. Diabetes Obes Metab. 2017 Sep;19 Suppl 1:137-146 - PubMed
  164. Cell Death Differ. 2019 Jul;26(7):1267-1282 - PubMed
  165. Mil Med Res. 2018 Jul 30;5(1):24 - PubMed
  166. J Exp Clin Cancer Res. 2018 Dec 27;37(1):324 - PubMed
  167. Curr Opin Immunol. 2018 Aug;53:152-160 - PubMed
  168. Oncogenesis. 2016 Aug 08;5(8):e250 - PubMed
  169. Front Immunol. 2020 Feb 07;11:161 - PubMed
  170. Front Immunol. 2019 Jul 12;10:1560 - PubMed
  171. Cancer Res. 2019 Apr 1;79(7):1293-1294 - PubMed
  172. Immunity. 2014 Sep 18;41(3):503 - PubMed
  173. Theranostics. 2020 Jan 12;10(4):1960-1980 - PubMed
  174. J Cell Commun Signal. 2020 Feb 7;: - PubMed
  175. Oncogene. 2017 Feb 2;36(5):639-651 - PubMed
  176. Oncotarget. 2015 Oct 6;6(30):29877-88 - PubMed
  177. Oxid Med Cell Longev. 2019 Apr 17;2019:5703764 - PubMed
  178. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Mar 3;:e1622 - PubMed
  179. Semin Cancer Biol. 2020 May;62:166-181 - PubMed
  180. Molecules. 2018 Dec 20;24(1): - PubMed
  181. Sci Adv. 2019 Nov 20;5(11):eaax8849 - PubMed
  182. Oncol Rep. 2017 Jul;38(1):522-528 - PubMed
  183. Mol Ther. 2020 Feb 5;28(2):503-522 - PubMed
  184. Cancer Res. 2020 Feb 15;80(4):922 - PubMed

Substances

MeSH terms

Publication Types

Grant support